Meeting
2014 ASCO Annual Meeting
Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: A report of the U.K. Managed Access Program.
Authors
Marco Maruzzo
Sarcoma Unit, Royal Marsden Hospital, London, United Kingdom
Marco Maruzzo , Attila Kollar , Charlotte Benson , Christina Messiou , Elizabeth Cartwright , Beatrice M. Seddon , Palma Dileo , Aisha Miah , Juan Martin-Liberal , Khin Thway , Ellen McGrath , Alison Dunlop , Ian Robert Judson , Mark David Linch
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Gastrointestinal Stromal Tumors (GIST)
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 10551)
DOI
10.1200/jco.2014.32.15_suppl.10551
Abstract #
10551
Poster Bd #
258
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
In vitro and in vivo activity of regorafenib (REGO) in drug-resistant gastrointestinal stromal tumors (GIST).
First Author: Cesar Serrano-Garcia
Poster
2022 ASCO Annual Meeting
KIT resistance mutations identified by circulating tumor DNA and treatment outcomes in advanced gastrointestinal stromal tumor.
First Author: Steven Bialick
Poster
2022 ASCO Annual Meeting
A randomized phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors.
First Author: Hyung-Don Kim
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Exploration of drug resistance in advanced gastrointestinal stromal tumor.
First Author: Hao Xu